85-2635-71　RWJ 67657 5mg　256542

特徴

• RWJ 67657 is an orally active inhibitor of the MAP kinases p38alpha and p38beta (IC50s = 1 and 11 uM, respectively, in vitro) that is inactive against p38gamma and p38delta, as well as several other kinases. It blocks the release of TNF-alpha and IL-1beta from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-alpha production in LPS-treated mice and rats. RWJ 67657 potently blocks the proliferation of CD4+ peripheral blood T cells induced by CD28 stimulation alone (IC50 = 0.5-4nM). It is commonly used to study the roles of p38alpha and p38beta in cellular and whole animal systems.
• Alternate Names:4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-phenylpropyl)-5-(4-Pyridyl)imidazole; JNJ 3026582; RWJ 67657
• Formula:C27H24FN3O
• Molecular Weight:~425.5
• λmax:241, 269 nm
• Purity:≥95%
• Appearance:Supplied as a crystalline solid.
• Solubility:~0.2mg/ml in a 1:4 solution of EtOH:PBS (pH 7.2); ~10mg/ml in EtOH; ~5mg/ml inDMSO; ~2mg/ml in DMF
• Storage and Stability:Store at 4°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.